Delivering Advanced Therapeutics
CP024 is in phase 1 clinical development where our intranasal spray has shown comparable activity to injection.
CriticalSorb enables the non-invasive nasal delivery delivery of high-value biologic products and challenging small molecule drugs.
CriticalMix enables the manufacture of highly active sustained release depot products for bimonthly, monthly or less frequent injection.
16th February 2012: Critical Pharma and University of Nottingham to Develop Nano-Enabled Nasal Spray for Osteoporosis.





